Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is set to announce its earnings results after the market closes on Wednesday, August 9th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.06. On average, analysts expect Aclaris Therapeutics to post $-3.21 EPS for the current fiscal year and $-3.46 EPS for the next fiscal year.

Shares of Aclaris Therapeutics, Inc. (ACRS) opened at 26.83 on Monday. The stock’s market capitalization is $717.25 million. Aclaris Therapeutics, Inc. has a one year low of $18.24 and a one year high of $33.25. The stock has a 50 day moving average price of $27.58 and a 200 day moving average price of $28.03.

A number of research analysts recently commented on ACRS shares. Jefferies Group LLC reiterated a “buy” rating and issued a $36.00 price objective on shares of Aclaris Therapeutics in a report on Monday, July 31st. BidaskClub upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, July 24th. Guggenheim reiterated a “buy” rating and issued a $40.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday, July 4th. ValuEngine upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Finally, Cantor Fitzgerald started coverage on Aclaris Therapeutics in a report on Friday, June 16th. They issued an “overweight” rating and a $50.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Aclaris Therapeutics presently has a consensus rating of “Buy” and an average target price of $39.00.

WARNING: “Aclaris Therapeutics, Inc. (ACRS) to Release Quarterly Earnings on Wednesday” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/07/aclaris-therapeutics-inc-acrs-to-release-quarterly-earnings-on-wednesday.html.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).

Earnings History for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.